FDAnews Device Daily Bulletin

TARGETED DRUG DELIVERY ACHIEVED WITH NANOPARTICLE-APTAMER BIOCONJUGATES

Nov. 7, 2005
A A

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates. Nucleic acid ligands (referred to as aptamers) are short DNA or RNA fragments that can bind to target antigens with high specificity and affinity; analogous to monoclonal antibodies.

EurekAlert! (http://www.eurekalert.org/pub_releases/2005-11/foec-tdd110105.php)